| Index | — | P/E | — | EPS (ttm) | 0.17 | Insider Own | 5.73% | Shs Outstand | 14.92M | Perf Week | -4.23% |
| Market Cap | 1.27B | Forward P/E | 24.95 | EPS next Y | 3.40 | Insider Trans | 0.09% | Shs Float | 14.54M | Perf Month | 1.41% |
| Enterprise Value | 1.63B | PEG | 38.09 | EPS next Q | 0.76 | Short Float | 8.22% | Perf Quarter | 11.92% | ||
| Income | -6.00M | P/S | 1.63 | EPS this Y | 10.19% | Short Ratio | 5.97 | Perf Half Y | 19.71% | ||
| Sales | 779.00M | P/B | 1.65 | EPS next Y | 17.81% | ROA | -0.48% | Short Interest | 1.19M | Perf YTD | 8.72% |
| Book/sh | 51.33 | P/C | 50.68 | EPS next 5Y | 13.11% | ROE | -1.27% | 52W High | 90.94 -6.64% | Perf Year | -1.53% |
| Cash/sh | 1.68 | P/FCF | 19.49 | EPS past 3/5Y | -24.81% -19.07% | ROIC | 5.25% | 52W Low | 58.19 45.90% | Perf 3Y | -0.04% |
| Dividend Est. | 1.84 (2.17%) | EV/EBITDA | 16.27 | Sales past 3/5Y | 12.20% 13.05% | Gross Margin | 19.17% | Volatility | 2.66% 3.09% | Perf 5Y | -18.48% |
| Dividend TTM | 1.83 (2.16%) | EV/Sales | 2.09 | EPS Y/Y TTM | -92.58% | Oper. Margin | 10.81% | ATR (14) | 2.65 | Perf 10Y | 38.39% |
| Dividend Ex-Date | Aug 21, 2026 | Quick Ratio | 1.27 | Sales Y/Y TTM | 17.14% | Profit Margin | -0.77% | RSI (14) | 48.98 | Recom | 2.23 |
| Dividend Gr. 3/5Y | 3.15% 41.26% | Current Ratio | 1.27 | EPS Q/Q | -7.41% | SMA20 | -1.04% | Beta | 1.11 | Target Price | 90.00 |
| Payout | — | Debt/Eq | 0.50 | Sales Q/Q | 30.49% | SMA50 | 2.35% | Rel Volume | 1.85 | Prev Close | 85.83 |
| Employees | 6,374 | LT Debt/Eq | 0.44 | Earnings | Nov 04 | SMA200 | 10.64% | Avg Volume | 180.77K | Price | 84.90 |
| IPO Date | May 29, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -7.81% 1.28% | Net Debt/EBITDA | 3.60 | Volume | 334,697 | Change | -1.08% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-13-26 | Reiterated | Barrington Research | Outperform | $98 → $90 |
| Mar-09-26 | Reiterated | Jefferies | Buy | $102 |
| Feb-28-25 | Reiterated | Barrington Research | Outperform | $98 |
| Dec-16-24 | Upgrade | B of A Securities | Neutral → Buy | |
| Oct-07-24 | Downgrade | B of A Securities | Buy → Neutral | |
| Sep-19-23 | Upgrade | CJS Securities | Market Perform → Market Outperform | |
| Dec-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform | |
| May-07-21 | Upgrade | Barrington Research | Market Perform → Outperform | |
| May-03-21 | Upgrade | Jefferies | Hold → Buy | |
| Feb-26-21 | Downgrade | Barrington Research | Outperform → Market Perform |
U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal conditions, recovery from sports-related trauma, proactive health measures, assistance for workers recovering from injuries, and care for neurological conditions. The company's business is divided into two primary divisions: Physical Therapy Operations and Industrial Injury Prevention Services. Within its industrial segment, it provides specialized services like on-site injury avoidance and recovery programs, strategies for enhancing physical performance, pre-employment screening tests, assessments of an individual's work capacity, and workplace ergonomic reviews. These offerings are delivered by licensed physical therapists and expert certified athletic trainers to a diverse clientele, including Fortune 500 corporations, insurance providers, and their associated contractors. By the end of 2021, specifically December 31st, the company had established 591 operational clinics across 39 states, in addition to overseeing 35 other physical therapy sites. Established in 1990, the company maintains its headquarters in Houston, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 779 | 781 | 671 | 605 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 630 | 624 | 547 | 483 | — | — | — | — | — | |
| Gross Profit | 150 | 157 | 124 | 122 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 14 | 0 | 58 | 0 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 52 | 77 | 3 | 69 | — | — | — | — | — | |
| Operating Income | 84 | 80 | 63 | 52 | — | — | — | — | — | |
| Interest Expense | 10 | 9 | 8 | 9 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7 | 7 | 5 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | 68 | 78 | 60 | 49 | — | — | — | — | — | |
| Income Taxes | 17 | 20 | 15 | 12 | — | — | — | — | — | |
| Consolidated Net Income | -6 | 15 | 26 | 15 | — | — | — | — | — | |
| Net Income From Continuing Operations | 50 | 58 | 46 | 37 | — | — | — | — | — | |
| Net Income | -6 | 15 | 26 | 15 | — | — | — | — | — | |
| EPS (Recurring) | 0.17 | 1.42 | 1.84 | 1.28 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.17 | 1.42 | 1.84 | 1.28 | — | — | — | — | — | |
| EPS (Diluted) | 0.17 | 1.42 | 1.84 | 1.28 | — | — | — | — | — | |
| EBITDA | 100 | 110 | 87 | 74 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 499.41 | 54.99 | 48.21 | 72.77 | — | — | — | — | — | |
| Price To Sales Ratio | 1.63 | 1.50 | 1.98 | 2.16 | — | — | — | — | — | |
| Gross Margin | 19.26 | 20.10 | 18.48 | 20.17 | — | — | — | — | — | |
| Operating Margin | 10.78 | 10.24 | 9.39 | 8.60 | — | — | — | — | — | |
| Net Margin | -0.77 | 1.92 | 3.87 | 2.48 | — | — | — | — | — | |
| Shares Outstanding | 15 | 15 | 15 | 14 | — | — | — | — | — | |
| Market Capitalization | 1,274 | 1,171 | 1,331 | 1,304 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Minan Peter Francis | Director | Sep 11 '26 | Buy | 79.00 | 5 | 416 | 3,217 | Sep 14 |
| Minan Peter Francis | Director | Jun 12 '26 | Buy | 66.50 | 1 | 58 | 3,212 | Sep 14 |
| Minan Peter Francis | Director | Jun 09 '26 | Buy | 61.50 | 288 | 17,712 | 3,211 | Jun 10 |
| Minan Peter Francis | Director | Jun 08 '26 | Buy | 63.14 | 492 | 31,065 | 2,923 | Jun 10 |
| REEVE GRAHAM D. | COO | Mar 11 '26 | Sale | 78.86 | 662 | 52,205 | 30,078 | Mar 12 |
| REEVE GRAHAM D. | COO | Mar 09 '26 | Sale | 78.52 | 1 | 79 | 0 | Mar 11 |
| REEVE GRAHAM D. | COO | Mar 06 '26 | Sale | 82.25 | 1,807 | 148,626 | 1 | Mar 11 |
| Binstein Richard | EVP Gen'l Counsel & Secretary | Mar 06 '26 | Sale | 81.64 | 3,000 | 244,920 | 24,867 | Mar 09 |
| REEVE GRAHAM D. | COO | Nov 24 '25 | Sale | 71.01 | 743 | 52,760 | 20,740 | Nov 25 |
| Gilmartin Kathleen A | Director | Nov 20 '25 | Buy | 69.00 | 4,000 | 276,000 | 24,786 | Nov 24 |
| HAM NANCY | Director | Sep 11 '25 | Sale | 81.71 | 600 | 49,026 | 1,994 | Sep 11 |
| Williams Eric Joseph | President and COO | Sep 05 '25 | Sale | 85.25 | 1,000 | 85,250 | 25,331 | Sep 08 |
| READING CHRISTOPHER J | Chairman of the Board and CEO | Sep 04 '25 | Sale | 83.53 | 2,000 | 167,060 | 114,088 | Sep 05 |
| HENDRICKSON CAREY P | Chief Financial Officer | Aug 25 '25 | Sale | 86.11 | 698 | 60,105 | 27,808 | Aug 25 |
| REEVE GRAHAM D. | COO | Aug 21 '25 | Sale | 84.97 | 763 | 64,832 | 21,483 | Aug 21 |